Daiichi, Alteogen to work on subcutaneous Enhertu; Roche ends Nykode deal

Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena:

Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Mediterranean diet linked to lower depression risk in older women

A study in the British Journal of Nutrition finds that adherence to the Mediterranean diet is inversely associated with depressive symptoms, particularly in older women,

February 25, 2024

Short-term, self-regulating therapies may help alleviate long COVID symptoms

A new UCLA-led study suggests that some people living with long COVID may be able to alleviate certain symptoms by using short-term, self-regulating therapies.

March 14, 2024

Bausch + Lomb seeks funding for $1.75B eye drop acquisition from Novartis

Dive Brief: Bausch + Lomb is seeking to raise almost $2 billion to fund the planned acquisition of Xiidra eye drops from Novartis. The eye

September 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.